Dyne Therapeutics Inc (DYN) - Total Liabilities
Based on the latest financial reports, Dyne Therapeutics Inc (DYN) has total liabilities worth $214.90 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Dyne Therapeutics Inc to track the company's year-over-year net asset growth rate.
Dyne Therapeutics Inc - Total Liabilities Trend (2007–2025)
This chart illustrates how Dyne Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Dyne Therapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.
Dyne Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Dyne Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs46.36 Billion |
|
Sunrise Communications AG
NASDAQ:SNRE
|
USA | $7.52 Billion |
|
OPENLANE, Inc.
NYSE:OPLN
|
USA | $3.36 Billion |
|
Corporación Moctezuma S.A.B. de C.V
MX:CMOCTEZ
|
Mexico | MX$3.31 Billion |
|
RAMSAY HLTH.CARE ADR/025
F:RMY0
|
Germany | €16.77 Billion |
|
Axcelis Technologies Inc
NASDAQ:ACLS
|
USA | $329.90 Million |
|
Gibson Energy Inc.
TO:GEI
|
Canada | CA$4.09 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Dyne Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Dyne Therapeutics Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dyne Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dyne Therapeutics Inc (2007–2025)
The table below shows the annual total liabilities of Dyne Therapeutics Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $214.83 Million | +249.91% |
| 2024-12-31 | $61.40 Million | -16.80% |
| 2023-12-31 | $73.79 Million | +36.75% |
| 2022-12-31 | $53.96 Million | -6.10% |
| 2021-12-31 | $57.47 Million | +423.99% |
| 2020-12-31 | $10.97 Million | +356.96% |
| 2019-12-31 | $2.40 Million | -81.74% |
| 2018-12-31 | $13.15 Million | -99.87% |
| 2017-12-31 | $9.87 Billion | -10.36% |
| 2016-12-31 | $11.01 Billion | +27.77% |
| 2015-12-31 | $8.62 Billion | +4.98% |
| 2014-12-31 | $8.21 Billion | +166.44% |
| 2013-12-31 | $3.08 Billion | +51.62% |
| 2012-12-31 | $2.03 Billion | -32.60% |
| 2011-12-31 | $3.02 Billion | -58.51% |
| 2010-12-31 | $7.27 Billion | -8.87% |
| 2009-12-31 | $7.97 Billion | -18.03% |
| 2008-12-31 | $9.73 Billion | +11.92% |
| 2007-12-31 | $8.69 Billion | -- |
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal mus… Read more